Loading...
XASE
TOVX
Market cap4mUSD
Jul 15, Last price  
0.47USD
1D
-1.00%
1Q
-63.82%
Name

Theriva Biologics Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-3.89%
Rev. gr., 5y
%
Revenues
0k
0000103,0893,164,51200000000000000
Net income
-26m
L+39.81%
-1,355,842-4,099,095-9,892,433-7,205,158-3,731,405-1,711,159-8,149,000-17,068,000-12,317,000-19,784,000-43,737,000-27,255,000-15,174,000-13,367,000-15,020,000-9,999,000-14,174,000-19,685,000-18,349,000-25,653,000
CFO
-17m
L-10.84%
-1,082,109-2,365,819-6,606,859-4,851,675-2,918,864-1,139,896-2,875,000-8,916,000-7,719,000-16,079,000-38,890,000-27,901,000-20,204,000-17,279,000-13,873,000-12,168,000-12,890,000-19,082,000-18,996,000-16,937,000
Earnings
Aug 11, 2025

Profile

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
IPO date
Feb 12, 1993
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
19,427
22,226
21,849
Unusual Expense (Income)
NOPBT
(19,427)
(22,226)
(21,849)
NOPBT Margin
Operating Taxes
(1,640)
(1,425)
Tax Rate
NOPAT
(19,427)
(20,586)
(20,424)
Net income
(25,653)
39.81%
(18,349)
-6.79%
(19,685)
38.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,563
2,219
1,718
BB yield
-235.80%
-32.03%
-24.65%
Debt
Debt current
600
1,037
273
Long-term debt
2,285
3,533
2,811
Deferred revenue
Other long-term liabilities
7,827
7,180
7,211
Net debt
(8,724)
(18,607)
(38,801)
Cash flow
Cash from operating activities
(16,937)
(18,996)
(19,082)
CAPEX
(1,000)
(202)
(116)
Cash from investing activities
(1,000)
(202)
(4,396)
Cash from financing activities
5,496
625
(1,930)
FCF
(18,788)
(21,223)
(20,484)
Balance
Cash
11,609
23,177
41,786
Long term investments
99
Excess cash
11,609
23,177
41,885
Stockholders' equity
(336,146)
(306,534)
(288,898)
Invested Capital
364,513
356,052
352,354
ROIC
ROCE
EV
Common stock shares outstanding
1,348
644
613
Price
1.75
-83.72%
10.75
-5.43%
11.37
 
Market cap
2,359
-65.94%
6,928
-0.62%
6,971
 
EV
(6,365)
(8,945)
(29,096)
EBITDA
(19,290)
(22,091)
(21,764)
EV/EBITDA
0.33
0.40
1.34
Interest
430
Interest/NOPBT